You can buy or sell XERS and other stocks, options, ETFs, and crypto commission-free!
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. Read More The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
52 Week High
52 Week Low
Associated PressMar 14
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
CHICAGO--(BUSINESS WIRE)--Mar 14, 2019--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has now begun dosing patients in a Phase 2 trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type 1 diabetes who experience episodes of exercise-induced hypoglycemia (EIH). “Many individuals with diabetes...
Simply Wall StFeb 26
What You Must Know About Xeris Pharmaceuticals, Inc.’s (NASDAQ:XERS) Financial Strength
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! While small-cap stocks, such as Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) with its market cap of US$264m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. Companies operating in the Pharmaceuticals industry, especially ones that are currently loss-making, are more likely to be higher risk. So, under...
Markets InsiderFeb 20
Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
CHICAGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference. Date: Wednesday, February 27, 2019 Time: 3:30 p.m. ET Place: L...
-$0.94 per share
-$0.98 per share